Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
NCT ID: NCT01880788
Last Updated: 2015-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
152 participants
OBSERVATIONAL
2012-11-30
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions
NCT02077894
Molecular Genetics of Retinal Degenerations
NCT00231010
Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia
NCT00265590
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714
Repository for Inherited Eye Diseases
NCT00378742
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CNV secondary to CSC
No interventions assigned to this group
CSC without CNV
No interventions assigned to this group
CNV secondary to advanced AMD
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 30 years and older (CSC)
* 50 years and older (Advanced AMD)
* Genders Eligible for Study: Both
* Completed Consent form
* Diagnosis of choroidal neovascularization in at least one eye
Exclusion Criteria
* Patient age less than 50 years (AMD).
* Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD and CSC such as high myopia, retinal dystrophies, retinal vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which have been present prior to the age of 30.
* Opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate fundus photography.
* Missing informed consent
* Previous sample donation under this protocol
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vitreous -Retina- Macula Consultants of New York
OTHER
Sequenom, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
K. Bailey Freund, MD
Clinical Associate Professor at NYU School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vitreous Retina Macula Consultants of New York
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCMM-AMD-107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.